DBV Technologies Reports Recent Business Developments and First Quarter 2022 Financial Results
DBV Technologies reported updates on the regulatory status of its lead product, Viaskin Peanut, following a Type C meeting granted by the FDA. This meeting is aimed at aligning on the new Phase 3 study protocol submitted as part of the FDA's briefing materials. Additionally, the company announced its first-quarter 2022 financial results, which were approved by the Board of Directors on April 29, 2022.
- FDA granted a Type C meeting to align on the Viaskin Peanut Phase 3 study protocol.
- None.
Montrouge, France, May 2, 2022
DBV Technologies Reports Recent Business Developments and First Quarter 2022 Financial Results
- The U.S. Food and Drug Administration (FDA) has granted DBV Technologies a Type C meeting to align on the new Viaskin Peanut Phase 3 study protocol
- The study protocol was recently submitted to the FDA as part of the Type C briefing materials
DBV Technologies S.A. (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage specialty biopharmaceutical company, today announced business updates concerning the regulatory status for its lead product candidate, Viaskin Peanut. The Company also reported financial results for the first quarter of 2022. The quarterly financial statements were approved by the Board of Directors on April 29, 2022.
To download the full version of the Press Release in English language, please click on the following link: PDF Version
Attachment
FAQ
What were the key updates from DBV Technologies on May 2, 2022?
What financial results did DBV Technologies report for the first quarter of 2022?
What is the status of the Viaskin Peanut product development?
